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Background: Vaccine failure is an important concern in the tropics with many contributing elements. Among
them, it has been suggested that exposure to natural infections might contribute to vaccine failure and recurrent
disease outbreaks. We tested this hypothesis by examining the influence of co-infections on maternal and infant
measles-specific IgG levels.
Methods: We conducted an observational analysis using samples and data that had been collected during a larger
randomised controlled trial, the Entebbe Mother and Baby Study (ISRCTN32849447). For the present study, 711
pregnant women and their offspring were considered. Helminth infections including hookworm, Schistosoma
mansoni and Mansonella perstans, along with HIV, malaria, and other potential confounding factors were
determined in mothers during pregnancy and in their infants at age one year. Infants received their measles
immunisation at age nine months. Levels of total IgG against measles were measured in mothers during pregnancy
and at delivery, as well as in cord blood and from infants at age one year.
Results: Among the 711 pregnant women studied, 66% had at least one helminth infection at enrolment, 41% had
hookworm, 20%M. perstans and 19% S. mansoni. Asymptomatic malaria and HIV prevalence was 8% and 10%
respectively. At enrolment, 96% of the women had measles-specific IgG levels considered protective (median 4274
mIU/ml (IQR 1784, 7767)). IgG levels in cord blood were positively correlated to maternal measles-specific IgG levels
at delivery (r = 0.81, p < 0.0001). Among the infants at one year of age, median measles-specific IgG levels were
markedly lower than in maternal and cord blood (median 370 mIU/ml (IQR 198, 656) p < 0.0001). In addition, only
75% of the infants had measles-specific IgG levels considered to be protective. In a multivariate regression analysis,
factors associated with reduced measles-specific antibody levels in infancy were maternal malaria infection, infant
malaria parasitaemia, infant HIV and infant wasting. There was no association with maternal helminth infection.
Conclusion: Malaria and HIV infection in mothers during pregnancy, and in their infants, along with infant malnutrition,
may result in reduction of the antibody response to measles immunisation in infancy. This re-emphasises the importance
of malaria and HIV control, and support for infant nutrition, as these interventions may have benefits for vaccine efficacy
in tropical settings.
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Despite the availability of a stable and effective vaccine,
measles outbreaks are still an important concern in Eastern
and Southern Africa. Although the Expanded Programme
on Immunisation (EPI) operates in many countries, there
are still issues that affect complete coverage in many coun-
tries, and this also contributes to the continuing measles
outbreaks throughout the world [1,2]. To prevent serious
outbreaks and deaths in the developing world, measles vac-
cinations are administered at 9 months of age [3]. Previous
studies have suggested that induction of protective immun-
ity against measles by immunisation in infants may be
influenced by a number of factors, including the rate of
decay of maternally acquired measles-specific antibodies
[4], and maternal infection with other pathogens during
pregnancy [5-9]. Age at immunisation [10,11], number
of doses and the measles vaccine strain used [12,13]
can also greatly influence the levels of antibody response.
In addition, it has been hypothesised that helminth infec-
tions might impact on the immunogenicity and efficacy
of vaccines [14] and the ability of the host to respond to
infections with other pathogens [15]. Moreover, it has
been hypothesised that in utero exposure of the child to
maternal helminth infection may have a long-term effect
on the child’s immunological development, including
their response to immunisation [16,17]. Contrary to this
hypothesis, within the Entebbe Mother and Baby study
(EMaBS), we have shown that anthelminthic treatment
during pregnancy had no effect on infant antibody levels
following measles immunisation [18]. However, we con-
sidered the possibility that maternal helminths might
have other effects on the infant response that are not
modified by treatment during pregnancy, or that other
chronic immunomodulating infections such as HIV or
malaria may influence the infant response to immunisa-
tion. We therefore explored these possibilities in an ob-
servational analysis within the EMaBS cohort, which had
been established for a trial of anthelminthic treatment
during pregnancy in Entebbe, Uganda.
Methods
Study setting and design
The Entebbe Mother and Baby Study (EMaBS) was a
larger, randomised, double-blind placebo controlled trial
of treatment of helminths in pregnancy with albendazole
versus placebo and praziquantel versus placebo in a 2x2
factorial design involving 2507 pregnant women and
their infants (trial registration number ISRCTN32849447).
The study design and trial results have previously been
reported [18,19].
For this study we conducted an observational ana-
lysis using samples and data that had been collected
during the EMaBS. The aims of this observational
analysis were1. to investigate the hypothesis that maternal helminth
infections influence maternal anti-measles antibody
levels, and the infant response to measles
immunisation, and
2. to investigate other factors associated with the infant
response to measles immunisation
Briefly, the study was based in Entebbe Hospital and
recruited participants from Entebbe municipality and
the adjacent Katabi sub-county, a population comprising
urban, rural and fishing communities. Pregnant women in
the second or third trimester were enrolled at Entebbe
Hospital antenatal clinic if they were resident in the study
area, planning to deliver in the hospital, willing to know
their HIV status and willing to take part in the study.
They were excluded if they had evidence of possible
helminth-induced pathology (severe anaemia, clinically
apparent liver disease, bloody diarrhoea), if the pregnancy
was abnormal, or if they had already enrolled during a
previous pregnancy [18]. Women gave written informed
consent for their own participation and for the participa-
tion of their infant in the study.
Women were followed up at delivery. Babies were
followed up at immunisation visits, at age six, nine and
12 months and quarterly thereafter to age five years; an-
nual follow up is still on-going.
The babies were immunised at birth with the Bacille
Calmette Guerin (BCG) and oral polio (OPV) vaccines;
at 6, 10 and 14 weeks with OPV, Diphtheria, tetanus, Per-
tussis, Haemophilus influenzae, hepatitis B vaccines; and
at nine months with measles vaccination. Immunisations
were usually given at the hospital immediately after deliv-
ery (BCG and OPV), or at the hospital outpatient depart-
ment adjacent to the research follow-up clinic. The place
at which the immunisation was given (Entebbe Hospital or
elsewhere) was documented. During the study period mea-
sles vaccines used at Entebbe Hospital were Edmonston
Zagreb strain (Serum Institute India Ltd), Edmonston
Zagreb strain (Measles Vaccine Vaksin) from Biofarma,
Indonesia and Schwarz strain (Rouvax) from Sanofi
Pasteur. The strain and manufacturer of vaccines given to
individual infants was not recorded.
Samples and laboratory methods
Sample collection
Samples collected were from mothers during pregnancy
and at delivery (stool and blood), from cord blood, and
from infants at age one year (stool and blood). Stool and
blood samples were used for diagnosis of intestinal and
systemic helminth infections, and blood samples for
malaria slides and HIV serology. Serum was aliquotted
and stored frozen (-80°C) at Uganda Virus Research Insti-
tute (UVRI) until the time of the measles antibody assay.
In addition, samples were collected from HIV-exposed
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PCR and serology, respectively. Infants were not sampled
at immunisation, so the effect of maternal anti-measles
antibody or of malaria or HIV infection at the time of im-
munisation on the induction of immune response to the
vaccine could not be determined.
Sample selection for measles analysis
The current observational analysis involved measure-
ment of measles-specific antibody levels for 711 mother-
baby pairs who had blood samples available from each of
four time points: from the mother at enrolment into the
study during the second or third trimester of the preg-
nancy, from the mother at delivery, from cord blood,
and from the infant at age one year. Mother-baby pairs
were included if the maternal delivery samples were
obtained within seven days after delivery and if the baby
had a clearly documented record of measles immunisa-
tion at 9 months, administered in Entebbe Hospital. One
from each set of twins was excluded from the analysis.
Measurement of measles antibody
Levels of measles-specific IgG antibody in serum was
measured by ELISA using a quantitative commercial kit
(Enzygnost, Germany) according to the manufacturer’s
protocol. Briefly, serum samples were added in duplicate
to a microtitre plate, which contained two parallel wells
coated with either whole measles virus antigen, or con-
trol antigen derived from non-infected cells. The testing
kit had an “anti-measles virus-reference” (Human serum
containing IgG antibodies to measles virus antigens) that
was included on each test run. The test kit had a sensi-
tivity of 99.6% and specificity of 100%, and could accur-
ately test samples containing a minimum 150 mIU/ml.
The serum samples were tested in a randomised se-
quence, but with all samples from each mother-baby pair
on the same plate. Measles-specific IgG antibody levels
were quantified using the α-method, reported in milli
international units per millilitre (mIU/ml) of serum or
plasma, by the following formula: log10 mIU/ml = α x A
β
(where α and β are lot-dependent constants, provided
by the manufacturer [6]). The values thus calculated
reflected the international standard for anti-measles serum
(1st international standard) of the WHO. A protective re-
sponse was defined as having a level of measles antibody
greater than 200 mIU/ml as reported elsewhere [4,18,20].
Parasitological procedures
Stool samples were collected before the study drug was
given to the study participants at the antenatal clinic in
Entebbe Hospital and were examined using the Kato
Katz method for helminth ova including hookworm and
S. mansoni [21,22]. The charcoal culture method was used
to examine for Strongyloides stercoralis [23-26]. Wholeblood samples were examined for M. perstans according
to a modified Knott’s method [27] and for malaria by
Leishman stained thick smears.
HIV screening
HIV sero-status of the women was determined at enrol-
ment into the study using a serial rapid testing algorithm
as previously reported [25]. For offspring of HIV positive
women, HIV viral load was measured at six weeks of age
using both DNA PCR and quantitative RT-PCR, to de-
termine vertical HIV transmission. HIV antibody testing
in infants was done at 18 months. Children were defined
as HIV infected if found positive on both PCR assays at
6 weeks, or on serology at 18 months, and as exposed
uninfected if found negative [18,28].
Data analysis
Data were analysed using Stata version 10 (College Station,
Texas,USA) with the following objectives: (1) to compare
measles antibody levels at the four time points (maternal
blood during pregnancy and after delivery, cord blood, and
at age one year); (2) to determine the associations between
maternal socio-demographic characteristics, infections
(helminths, HIV, malaria) and maternal antibody levels;
(3) to determine the associations between maternal and
childhood characteristics, helminth infections, HIV, mal-
aria and the infant response to measles immunisation.
Characteristics of the study population were summarised
using frequencies for categorical variables, with means and
medians for continuous variables. Antibody levels showed
skewed distributions and were therefore log-transformed
for analysis. Correlations between log antibody levels at
each time point were examined using Pearson’s correlation
coefficient. Paired t-tests were also done to assess whether
the actual levels of antibody differed between each time
point. Chi-squared tests were used to examine associations
between maternal/child characteristics and presence of
protective antibody levels. Simple linear regression was
then used to examine crude associations between each
potential risk factor and maternal log antibody levels,
and between each potential risk factor and infant log
antibody levels. The following variables were examined
for possible association with maternal measles antibody
levels: maternal age, education, marital status, maternal
tribe, socio-economic status, gravidity, HIV status, CD4
counts, asymptomatic malaria, worm infection, worm in-
fection intensity, and gestation stage at enrolment. The
same variables were considered for possible association
with infants’ measles-specific antibody levels, with the
addition of baby’s birth weight, baby’s sex, number of
malaria episodes during infancy, infant asymptomatic
malaria at age one year, infant HIV, and wasting and
stunting at one year of age. Multivariable linear regression
models were then developed for each factor that showed
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crude analysis. Using a causal diagram, these models were
adjusted for any distal or concurrent variables that also
showed some evidence of association with the outcome
based on crude analysis. For example, associations between
maternal infections and maternal antibody levels were ad-
justed for any maternal socio-demographic factors or con-
current infections that showed association with antibody
levels in the crude analysis, but associations between socio-
demographic factors and maternal antibody levels were not
adjusted for infections since these may be on the causal
pathway between the socio-demographic factor and anti-
body levels.
Ethical considerations
Ethical approval was granted by the UgandaVirus Research
Institute Science and Ethics Committee, the Ethics com-
mittee of the London School of Hygiene and Tropical
Medicine, and the Uganda National Council of Science
and Technology.
Results
Among the 711 mothers included in this study, 41%
had hookworm at enrolment, 20%M. perstans, and
19% S. mansoni. Sixty six percent of the women had at
least one helminth species. Among women with hook-
worm and S. mansoni, 4% and 10% respectively had heavy
infection intensities. The prevalence of maternal asymp-
tomatic malaria and maternal HIV was 8% and 10% re-
spectively. Of the 74 HIV positive mothers, 22 had CD4
counts less than 350 cells/μl. The mean age of women at
enrolment was 24 years with the youngest being 14 years
and the oldest 47 years. Median maternal gestational age
was 26 weeks at enrolment. Half of the pregnant women
had attained at least a primary level education. Almost 58%
of the women reported having had more than two previous
pregnancies. At least 98% of the women had a full term de-
livery (38–42 weeks gestation). The mean number of
people per household was 3.7 and the mean household in-
come was less than 30,000 Uganda Shillings per month.
Mothers who were included in this study were on
average older and more educated, and were less likely to
be infected with hookworm and malaria, than those
EMaBS cohort members who were not included in this
study. There were no other significant differences be-
tween the two groups.
The mean birth weight of children in this sample was
3.2 kg (range of 1.3-4.9 kg). At age one year, 92 (13%)
children were considered to be stunted and 27 (4%) had
evidence of wasting. No cases of underweight infants
were observed. Sixty-two children (9%) were exposed to
HIV but were uninfected and 12 (2%) were HIV infected.
Forty children (6%) at age one year had asymptomatic mal-
aria infection.Maternal and cord measles antibody levels
The Median (IQR) measles-specific antibody levels in
mothers at enrolment and delivery, and in cord blood,
were very similar (4274 mIU /ml (IQR 1784, 7767),
4079 mIU/ml (IQR 1802, 7854) and 4176 mIU/ml (IQR
1932, 8247), respectively), although the mean level at deliv-
ery was slightly lower than the level in cord blood (paired
t-test p = 0.02; Figure 1). Maternal measles-specific IgG
antibody levels were highly correlated between enrol-
ment and delivery (r = 0.81; p < 0.0001). Maternal and cord
blood measles specific IgG levels were also highly corre-
lated (r = 0.82; p < 0.0001). Of the women enrolled in the
study, 96% had measles-specific IgG levels within the pro-
tective range at enrolment.
In crude linear regression analyses of the factors asso-
ciated with maternal measles antibody levels at enrol-
ment in this cohort, we found that only maternal age,
gravidity, and asymptomatic malaria infection were asso-
ciated with antibody levels (p < 0.1; Table 1). However, in
multivariable models, the association with gravidity was
no longer statistically significant after adjusting for ma-
ternal age, and the association with malaria was no lon-
ger statistically significant after adjusting for maternal
age and gravidity. Thus, only maternal age at the time of
enrolment in the study was associated with increased
measles-specific IgG levels (Table 1).
Of note, maternal HIV, maternal helminth infections
and anthelmintic treatment during pregnancy showed
no associations with maternal or cord blood measles
antibody levels (data not shown). Similar trends were
observed for measles antibody levels in maternal blood
at delivery and in cord blood.
Measles antibody levels at age one year
Measles-specific IgG antibody levels among the infants
at age one year were significantly lower than maternal
or cord blood levels (median 370 mIU/ml (IQR 198,
656), paired t-test on logged values p < 0.0001; Figure 1).
They showed no correlation with maternal (r = −0.05;
p = 0.14) or cord blood levels (r = −0.02; p = 0.54). Of par-
ticular concern, only 75% of the infants at age one year
were found to have antibody levels considered protective
against measles.
In a multivariable analysis of factors associated with
the infant response to measles immunisation, we found
that higher maternal gravidity was associated with higher
measles-specific IgG levels, while maternal asymptomatic
malaria was associated with lower levels in the offspring
(Table 2). Infant wasting showed a negative association
with measles-specific IgG levels and infants infected
with malaria or HIV also had lower antibody levels than
their uninfected counterparts. Maternal helminth infec-
tions showed no associations with infant measles-specific
























Figure 1 Measles-specific IgG antibody levels in cord, infants and their mothers. Paired t-test values.
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maternal anthelminthic treatment.
Discussion
Measles-specific IgG levels are widely used as proxy
measures of immunity in measles immunisation
programmes. The presence of measles-specific IgG anti-
bodies in sera indicates either a previous infection, orTable 1 Factors associated with measles antibody levels in m
Univariable analyses
Explanatory variable Status Mean(SD) log IgG Mean d
(95% confide
Gravidity 1 3.42 (0.55)
2-4 3.54 (0.49) 0.13 (0.0
5+ 3.61 (0.47) 0.20 (0.0
Asymptomatic malaria No 3.53 (0.50)
Yes 3.40 (0.59) −0.13 (−0
Maternal age in years 14-19 3.38 (0.52)
20-24 3.52 (0.51) 0.14 (0.0
25-29 3.57 (0.49) 0.19 (0.0
30-34 3.65 (0.44) 0.27 (0.1
35+ 3.57 (0.46) 0.19 (−0
SD standard deviations; 1in multivariable analyses, asymptomatic malaria was adjus
2likelihood ratio test; the mean IgG levels observed at maternal enrolment were simsuccessful immunisation [1,20,29,30]. This current study
presents an observational analysis of the associations be-
tween co-infections and levels of measles-specific IgG
antibodies in a cohort of pregnant women and their in-
fants. Our findings indicate that maternal helminth in-
fection during pregnancy does not influence the levels of
measles-specific antibodies in their offspring at age one








4, 0.22) 0.05 (−0.05, 0.15)
8, 0.31) 0.06 (−0.10, 0.22)
0.07 0.26
.27, 0.01) −0.08(−0.22, 0.06)
0.0005 0.0005
4, 0.24) 0.14 (0.04, 0.24)
8, 0.30) 0.18 (0.08, 0.29)
4, 0.40) 0.27 (0.14, 0.40)
.01, 0.39) 0.18 (−0.01, 0.38)
ted for age and gravidity, gravidity was adjusted for age, age was unadjusted
ilar to maternal delivery and cord blood levels.
Table 2 Multivariable analysis of factors associated with infants measles log10 antibody responses at one year of age,
following immunisation at 9 months
Univariable analysis Multivariable analysis1
Explanatory variable Status Proportion (%)
with protective
antibody levels









Gravidity 1 147/184 (80) 0.009 2.54 (0.48) 0.06 0.06
2–4 310/413 (75) 2.55 (0.51) 0.01 (−0.08, 0.10) 0.01 (−0.08, 0.10)
5+ 73/114 (64) 2.42 (0.57) −0.12 (−0.24, 0.001) −0.12(−0.24, 0.001)
Maternal malaria infection No 484/646 (75) 0.3 2.54 (0.51) 0.09 0.05
Yes 37/54 (68) 2.41 (0.67) −0.13 (−0.27, 0.02) −0.14 (−0.29, 0.002)
Infant asymptomatic
malaria at age one year
No 486/647 (75) 0.07 2.54 (0.51) 0.003 0.003
Yes 25/40 (62) 2.29 (0.59) −0.25 (−0.42, -0.09) −0.25 (−0.41, -0.08)
Infant HIV Unexposed 482/637 (76) 0.003 2.54 (0.50) 0.002 0.003
Exposed,
uninfected
44/62 (71) 2.48 (0.54) −0.06 (−0.19, 0.07) −0.05 (−0.18, 0.09)
Infected 4/12 (33) 2.02 (0.85) −0.52( −0.82, -0.23) −0.50 (−0.80, -0.21)
Weight-for length/height
(wasting)
No 514/684 (75) 0.06 2.54 (0.50) 0.01 0.04
Yes 16/27 (59) 2.28 (0.78) −0.26 (−0.45, -0.06) −0.21 (−0.41, -0.01)
SD Standard deviation; 1in multivariable analyses, maternal asymptomatic malaria was adjusted for gravidity, infant asymptomatic malaria and HIV were adjusted
for each other and for gravidity and maternal malaria infection, wasting was adjusted for all other variables in the table 2chi2 test 3likelihood ratio test.
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between Th1, Th2 and Treg pathways by preventing Th1
responses and promoting a Th2 bias, thereby impairing re-
sponses to viral vaccines given to infants [15,31]. However,
neither this observational analysis, nor our other published
data [18], support the argument of Labeaud et al. that
treatment of antenatal helminth infections would improve
infant responses to immunisations [14].
We found that infants born of mothers infected with
malaria had reduced levels of measles-specific IgG at
age one year when compared with infants of uninfected
mothers. Malaria is well known to be immunosuppres-
sive [32] and it may be that malaria infection in the
mother creates an intra-uterine environment that has a
long-term effect on the infant response to infection and
immunisation. However, in this cohort, as in other studies
[33], maternal malaria was also associated with infant mal-
aria incidence (data not shown), so this result might also
simply reflect a direct effect of higher infant exposure to
malaria. In keeping with this hypothesis, infants with
asymptomatic malaria also had lower anti-measles anti-
body levels than uninfected infants. Our findings are in ap-
parent contradiction to a previous study performed in
Guinea Bissau in 1983/4 in children aged 8–19 months
that showed an increase in measles-specific responses after
a malaria infection [34]. However, in this paper, the authors
used measles infected Vero cells as the target antigen for
their ELISA, whereas we used a commercial kit that sup-
plies purified measles protein. It is possible that both stud-
ies are correct, as presumably the study by Smedman andcolleagues may have more measles epitopes to bind anti-
body than that supplied in the standard commercial kits of
today. Moreover, the timing of assessments was different
between the two studies, with most children in the earlier
study infected with malaria at the time of measles im-
munisation. In our study the malaria assessment was
made at the time of assessing the antibody response. We
do not know whether our infants had malaria at the time
of immunisation.
With regard to maternal HIV infection, measles-specific
antibody levels were similar in infants of uninfected
women and in HIV-exposed but uninfected infants,
but HIV infected infants had much lower antibody levels.
The infants’ HIV status was defined based on samples
obtained at 6 weeks and/or 18 months of age – not at nine
months when immunisation was given, nor at one year
when the measles antibody assays were performed. This
means that a small number of infants may have been mis-
classified; if this is so then our result, although striking,
may have underestimated the adverse effect of HIV positiv-
ity in the child. Although our study included only a small
number of HIV infected infants, these findings are consist-
ent with studies performed elsewhere [8,9,35,36]. However,
our findings for measles immunisation in HIV exposed but
uninfected children were different from those reported for
hepatitis B, diphtheria and tetanus immunisation in a study
in Brazil in which antibody responses were found to be re-
duced in this group [37]. This may be related to differences
in effect between live and subunit vaccines: within EMaBS
we also found that HIV exposed, uninfected infants had
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anus immunisation, but not to mycobacterial antigen fol-
lowing BCG immunisation [38].
Infant wasting (low weight for length) was associated
with reduced measles-specific IgG levels. Infant wasting
could be attributable to poor nutrition, which clearly has
detrimental effects on the immune system, and this may
explain why we saw an effect of infant wasting. This, again,
is in apparent contradiction with an earlier study [39], but
may again be reconciled by the use of different techniques
to calculate measles titres. In their study, McMurray and
colleagues used a common technique at the time to meas-
ure measles antibody titres, the hemagglutanin inhibition
(HI) assay. At around the same time, Nuemann and col-
leagues [40] published comparison data showing that both
antihemolysin (AH) and ELISA techniques were more sen-
sitive and specific than the traditional HI assay. It is thus
possible that the original HI assay may be less sensitive and
specific than the kits of today, leading the authors to con-
clude that malnutrition had no effect on measles antibody
titres in comparison to our data.
Our study therefore suggests that malaria, HIV and nu-
trition have more important implications for levels of
measles-specific antibodies in the first year of life than hel-
minth infections. Indeed, in places of high HIV prevalence
and incidence, HIV infected infants are suspected to con-
tribute to the transmission and sustainability of measles
virus outbreaks in the sub Saharan region [1].
In Uganda, the national measles immunisation coverage
(routine and campaign) increased from 63% in 2001 to
90% in 2004, and a slight drop to 85% in 2007 [41]. The
current coverage is estimated to be at 71%, although the
national sero-conversion rates among immunised children
is not known. We found that measles-specific antibody
levels in the infants were much lower than the levels in
their mothers. This is presumed to be due to the fact that
infants had not been exposed to natural measles infection.
In this study period (2003 to 2005) there were only two
cases of measles confirmed amongst the cohort before the
nine month vaccination [18], therefore actual cases are un-
likely to have had an impact on our results, and there was
no reported measles outbreak in the country [42]. In
addition, none of the infants included in this study had
prior documented measles immunisation below 9 months
of age. All infants who presented with a measles-like illness
were tested for antibodies and of these, a small number
had rubella IgG antibodies and the rest were not infected
with either rubella or measles. However, despite the fact
that all infants who participated in this study were
immunised at nine months of age at Entebbe district re-
ferral hospital with proper monitoring, only 75% of the
infants at one year of age had measles-specific IgG levels
considered protective against measles infection. The rea-
sons for this poor response are not clear. One possibleexplanation might lie in the high levels of maternal anti-
body, which is well known to interfere with infant re-
sponses to measles immunisation. Although we did not
collect information on maternal measles immunisation,
the high titres in the mothers might imply that they had
multiple exposures to the measles virus, either through
immunisation and exposure to the natural infection, or
multiple exposures to the natural infection. Such a sce-
nario may easily boost the immune response to measles
and maintain antibody titres at a high level.
Other possible explanations include inherent (for ex-
ample genetic) differences among the immunised infants
(which we are currently exploring) or differences in the
strain of vaccine itself, as well as the potency of the vaccine
at the time of administration. These issues surrounding the
vaccine strain or potency we were unable to exclude, as
this information was not captured at the time of immun-
isation, and the hospital itself does not keep records of
such information.Conclusions
In conclusion, we have found no evidence that maternal
helminth infection influences the infant response to mea-
sles immunisation, whereas control of malaria and HIV in-
fection in mothers and their infants, and support for infant
nutrition, may have benefits for measles vaccine efficacy.
The high proportion of infants in whom the vaccine failed
to induce a protective response (25%) supports the need
for measures aimed at improving the efficacy of initial
measles immunisation, and for revaccination campaigns, in
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